Recent advances in ovarian cancer treatment are moving toward personalized and targeted therapies, improving outcomes for advanced or recurrent disease. Targeted drugs like PARP inhibitors (e.g., olaparib, niraparib) exploit DNA repair defects in tumors with BRCA mutations or homologous recombination deficiency, often as maintenance therapy after chemotherapy. Angiogenesis inhibitors, such as bevacizumab, block tumor blood vessel growth, while antibody-drug conjugates like mirvetuximab soravtansine deliver chemotherapy directly to cancer cells expressing folate receptor alpha.
Immunotherapy approaches are also expanding. Immune checkpoint inhibitors, including pembrolizumab and dostarlimab, activate the immune system in tumors with high microsatellite instability. Investigational cellular therapies, such as memory-like natural killer cells, aim to create a durable anti-tumor response.
Surgical innovations enhance precision and outcomes. Fluorescence-guided surgery highlights tumors for more effective removal, while minimally invasive techniques reduce recovery time. Precision medicine and combination therapies, guided by genetic and molecular tumor profiling, are being explored to overcome drug resistance and improve individualized care.